Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
出版年份 2019 全文链接
标题
Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
作者
关键词
Parkinson’s disease dementia, α-Synuclein, Glucocerebrosidase, Ambroxol, Cognition
出版物
BMC Neurology
Volume 19, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-02-09
DOI
10.1186/s12883-019-1252-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate
- (2017) Anna Migdalska-Richards et al. SYNAPSE
- A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers
- (2017) Shi-Yu Yang et al. Stem Cell Reports
- Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice
- (2016) Anna Migdalska-Richards et al. ANNALS OF NEUROLOGY
- Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
- (2016) Aya Narita et al. Annals of Clinical and Translational Neurology
- Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders
- (2015) Giancarlo Parenti et al. MOLECULAR THERAPY
- Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
- (2014) Karen E. Murphy et al. BRAIN
- Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
- (2014) Alisdair McNeill et al. BRAIN
- Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators
- (2014) Ania C. Muntau et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Cognitive impairment and dementia in Parkinson's disease: Practical issues and management
- (2014) Murat Emre et al. MOVEMENT DISORDERS
- The neurobiological basis of cognitive impairment in Parkinson's disease
- (2014) Glenda M. Halliday et al. MOVEMENT DISORDERS
- Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease
- (2014) Katherine H O Deane et al. BMJ Open
- The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
- (2013) Caroline H Williams-Gray et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Predictors of Parkinson's disease dementia: Towards targeted therapies for a heterogeneous disease
- (2013) Sarah F. Moore et al. PARKINSONISM & RELATED DISORDERS
- Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
- (2013) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
- (2012) Matthew E. Gegg et al. ANNALS OF NEUROLOGY
- Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease
- (2012) Ari Zimran et al. BLOOD CELLS MOLECULES AND DISEASES
- The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice
- (2012) Zhuo Luan et al. BRAIN & DEVELOPMENT
- The link between the GBA gene and parkinsonism
- (2012) Ellen Sidransky et al. LANCET NEUROLOGY
- Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study
- (2012) Bruno Dubois et al. MOVEMENT DISORDERS
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies
- (2011) Joseph R. Mazzulli et al. CELL
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
- (2011) Olivier Rascol et al. LANCET NEUROLOGY
- Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models
- (2011) Y.H. Xu et al. MOLECULAR GENETICS AND METABOLISM
- CNS expression of glucocerebrosidase corrects -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy
- (2011) S. P. Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
- (2009) Gustavo H. B. Maegawa et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease
- (2009) Paolo Barone et al. MOVEMENT DISORDERS
- Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism
- (2009) Amy B. Manning-Boğ et al. NEUROTOXICOLOGY
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
- (2009) C. Warren Olanow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ambroxol in the 21st century: pharmacological and clinical update
- (2008) Mario Malerba et al. Expert Opinion on Drug Metabolism & Toxicology
- Parkinson's disease-cognitive rating scale: A new cognitive scale specific for Parkinson's disease
- (2008) Javier Pagonabarraga et al. MOVEMENT DISORDERS
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Dementia and survival in Parkinson disease: A 12-year population study
- (2008) T. C. Buter et al. NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started